Xermelo (Telotristat Etiprate) Patent Expiration, LOE Window & CMS Spending

Xermelo (Telotristat Etiprate) by Tersera Therapeutics: FDA Orange Book core substance LOE 2031-02-28, 0 AB generics, $24.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTersera Therapeutics
FDA Application & PathwayN208794 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-28
Last Listed Patent or Exclusivity Date2031-02-28
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$24.2M
2024 Medicare Part D Spend$24.2M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 48.9% 2-yr change)